<DOC>
	<DOCNO>NCT01702324</DOCNO>
	<brief_summary>The purpose study determine efficacy DD-25 , new topical drug , plaque Psoriasis Vulgaris . The study include subject plaque stage 5-20 % body area involvement . A total 30 subject treat cream application affect area twice daily three weeks.The efficacy preparation document PASI score , Global physician assessment photo .</brief_summary>
	<brief_title>Evaluation DD-25 Topical Cream Treatment Psoriasis Vulgaris : Proof Concept Study</brief_title>
	<detailed_description>Psoriasis Vulgaris remain widespread clinical entity chronic outflares various regimen treatment , none definitive . A new safe efficacious , external treatment require .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subject age 1860 2 . Diagnosis PS dermatologist lesion arm , leg trunk 3 . Subjects stable plaque PS , mild moderate form , Body Surface Area 520 % . 4 . Subject understood sign informed consent form 1 . Guttate , erythrodermic , palmplantar pustular psoriasis sole predominant form psoriasis . 2 . Hypersensitivity sunlight ; history Lupus , PMLE , disease know worsened UV light exposure 3 . Pregnancy , breast feeding 4 . History cancer , exclude nonmelanoma skin cancer . 5 . Patients history ischemic heart disease ( e.g . angina pectoris , myocardial infarction ) ; cerebrovascular syndrome , peripheral vascular uncontrolled hypertension . Subjects know severe hepatic and/or severe renal insufficiency . 6 . Any medical condition , opinion Investigator , would jeopardize health patient course study . 7 . Systemic treatment biological therapy possible effect psoriasis vulgaris within 4 month 5 drug halflives prior checkup . 8 . Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ) within 8week period prior randomization . Subjects use within 8 week period prior randomization PUVA Phototherapy . Use SSRI MAO inhibitor . 9 . Subjects use one follow TOPICAL drug treatment PS within 2 week prior randomization : e.g . WHO group III corticosteroid , retinoids , Vit . D analogue , immunomodulators , Anthracene derivative , Salicylic acid . 10 . Subjects current participation interventional clinical subject concomitant dermatological disorder ( ) might preclude accurate evaluation psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Plaque</keyword>
	<keyword>Topical</keyword>
	<keyword>Treatment</keyword>
</DOC>